AbbVie (ABBV) Q1 2025: Immunology and Neuroscience Outperform as Humira Declines Sharpen
AbbVie delivered a robust Q1 2025, with total revenues of $13.3 billion, up 9.8% operationally, and strong beats from immunology and neuroscience offsetting accelerated Humira erosion. Management raised full-year guidance, citing exceptional momentum in Skyrizi and Rinvoq, while acknowledging near-term headwinds in aesthetics and ongoing tariff and pricing policy uncertainty. The company’s deep pipeline and manufacturing investments signal a multi-year growth runway, but legacy product declines and external policy risks remain active watchpoints.
Summary
- Immunology and Neuroscience Drive Outperformance: Skyrizi and Rinvoq sales surged, with combined immunology revenue topping $6.2 billion and neuroscience up 17% YoY.
- Legacy Erosion Intensifies: Humira sales fell 49.5% operationally, with faster-than-expected biosimilar share loss prompting a guidance cut for the franchise.
- Pipeline and Capital Allocation Signal Long-Term Growth: Management emphasized a high single-digit revenue CAGR through 2029, supported by pipeline progress and $10 billion in planned U.S. manufacturing investment.
- Tariff and Policy Risks Remain Unquantified: Guidance excludes potential impacts from sectoral tariffs and evolving drug pricing policy, with mitigation strategies under review.
Performance Analysis
AbbVie’s Q1 2025 results outpaced expectations, with adjusted EPS of $2.46 (up $0.10 above guidance midpoint) and total revenues of $13.3 billion, nearly $550 million ahead of plan. Growth was driven by immunology, where Skyrizi and Rinvoq combined for $5.1 billion in sales, up more than 65%, and by neuroscience, which climbed 17% operationally to $2.3 billion. Oncology also delivered, with Venclexta up 12.3% and emerging solid tumor assets gaining traction.
Humira, once AbbVie’s cornerstone, saw revenue drop sharply to $1.1 billion, down nearly 50% operationally, as biosimilar competition and molecule compression accelerated. Aesthetics, including Botox Cosmetic and Juvederm, declined 10.2% as macro headwinds and consumer sentiment weighed on the category. Adjusted gross margin held at 84.1%, with R&D investment rising to 15.4% of sales, reflecting pipeline prioritization.
- Immunology Upside: Skyrizi and Rinvoq outperformed, prompting a $900 million increase in full-year sales guidance for these assets.
- Neuroscience Strength: Vraylar, Botox Therapeutic, and migraine therapies all exceeded expectations, with broad-based growth across indications.
- Legacy Drag: Humira’s faster-than-expected erosion and aesthetics softness offset some of the growth, but were anticipated in guidance revisions.
Overall, AbbVie’s diversified growth engines are absorbing legacy headwinds, but the pace of Humira’s decline and aesthetics volatility underscore the need for sustained execution in newer franchises.
Executive Commentary
"AbbVie is off to an excellent start to the year, with first quarter results exceeding expectations across several of our therapeutic areas...We are well positioned to exceed our previous peak revenue in just the second full year following the US Humira LOE."
Rob Michael, Chief Executive Officer
"We reported adjusted earnings per share of $2.46, which is 10 cents above our guidance midpoint...Total net revenues were more than $13.3 billion, reflecting robust growth of 9.8% on an operational basis."
Scott Runtz, Chief Financial Officer
"Skyrizi and Rinvoq are performing exceptionally well, contributing $5.1 billion in combined sales this quarter, reflecting growth of more than 65%...Overall, Skyrizi and Rinvoq are demonstrating impressive results across all of their approved indications, and we will be raising our full-year sales guidance for both products."
Jeff Stewart, Chief Commercial Officer
Strategic Positioning
1. Immunology Leadership and Lifecycle Transition
Skyrizi, IL-23 inhibitor, and Rinvoq, JAK inhibitor, are now AbbVie’s primary growth engines, capturing significant share in inflammatory bowel disease (IBD), dermatology, and rheumatology. Their strong efficacy and safety profiles have driven rapid adoption, particularly in Crohn’s and ulcerative colitis. The company is leveraging these assets’ lifecycle with new indications and combination trials to sustain momentum as Humira, anti-TNF biologic, faces steep decline.
2. Neuroscience and Oncology Pipeline Depth
Neuroscience franchises (notably Vraylar and migraine portfolio) and emerging oncology assets are broadening AbbVie’s revenue base. The company is investing in next-generation antibody-drug conjugates (ADCs) and advancing multiple late-stage programs, including Tevapidon for Parkinson’s and ABBV383 for multiple myeloma. These assets are positioned as future growth pillars beyond immunology.
3. Capital Allocation and U.S. Manufacturing Expansion
AbbVie is committing over $10 billion in U.S. manufacturing investment over the next decade, supporting volume growth, pipeline launches, and potential tariff mitigation. This strategic move also aligns with evolving policy incentives for domestic production and positions AbbVie competitively against regulatory and trade headwinds.
4. Navigating Policy and Tariff Uncertainty
Management is proactively monitoring U.S. drug pricing reform, sectoral tariffs, and global trade shifts, but current guidance excludes unquantified impacts. AbbVie’s large U.S. manufacturing base and diversified pipeline provide some insulation, though management acknowledges mitigation levers may be limited if tariffs expand.
5. R&D and Business Development for Long-Term Growth
Recent acquisitions (Nimble Therapeutics, Gubra partnership) and pipeline advances in obesity, oral peptides, and ADCs reflect AbbVie’s strategy to build a durable innovation engine. The company is pursuing a high single-digit revenue CAGR through 2029, with a focus on five key growth areas and continued business development in high unmet-need segments.
Key Considerations
AbbVie’s Q1 2025 results reinforce a multi-year growth thesis anchored in immunology and neuroscience, while exposing the urgency of offsetting legacy erosion and navigating external risks.
Key Considerations:
- Immunology Franchise Transition: Skyrizi and Rinvoq have successfully replaced Humira as AbbVie’s growth drivers, but sustaining high growth rates will require continued indication expansion and competitive differentiation.
- Pipeline Execution Criticality: Multiple late-stage readouts and regulatory filings in oncology, neuroscience, and obesity will shape revenue visibility and valuation in coming years.
- Aesthetics Volatility: Economic headwinds and consumer sentiment continue to pressure the aesthetics business, with only modest tariff impacts absorbed in guidance.
- Policy and Tariff Overhang: Drug pricing reform and potential sectoral tariffs remain unquantified risks, with mitigation options limited by contractual and government pricing structures.
Risks
AbbVie faces material risks from accelerating Humira erosion, policy-driven pricing pressures, and potential sectoral tariffs that could impact cost structures and margins. The company’s guidance does not incorporate unannounced trade or pricing actions, and further macroeconomic weakness could dampen aesthetics recovery. Pipeline execution, particularly in new modalities and high-competition categories, remains a key variable for long-term growth.
Forward Outlook
For Q2 2025, AbbVie guided to:
- Net revenues of approximately $15 billion (including 0.3% FX headwind)
- Adjusted operating margin ratio of roughly 49.5%
- Adjusted EPS between $3.26 and $3.30 (excluding future IPR&D expense)
For full-year 2025, management raised guidance:
- Adjusted EPS of $12.09 to $12.29
- Total net revenues of approximately $59.7 billion
- Skyrizi global sales of $16.5 billion, Rinvoq $8.2 billion, U.S. Humira $3.5 billion, Aesthetics $5.1 billion
Management highlighted that guidance excludes potential impacts from future tariffs, with mitigation focused on supply chain actions, cost efficiencies, and U.S. manufacturing expansion.
Takeaways
AbbVie’s Q1 highlights a successful pivot to new immunology and neuroscience franchises, strong pipeline momentum, and prudent capital allocation, but also underscores persistent legacy and policy risks.
- Diversified Growth Cushion: Robust Skyrizi, Rinvoq, and neuroscience performance are absorbing Humira and aesthetics pressures, validating AbbVie’s portfolio transition strategy.
- Pipeline and Investment Focus: R&D and U.S. manufacturing commitments support long-term growth, but require continued execution and regulatory success.
- External Headwinds Remain: Policy, tariff, and pricing risks are not fully reflected in guidance, and will require close monitoring as 2025 progresses.
Conclusion
AbbVie delivered a high-quality beat in Q1 2025, with new franchises driving growth and management raising full-year guidance despite legacy headwinds and policy uncertainty. Sustained pipeline execution and careful navigation of external risks will determine whether AbbVie’s growth thesis holds through the decade.
Read-Through
AbbVie’s results offer a roadmap for large-cap biopharma navigating patent cliffs and policy volatility: rapid immunology franchise transition, deep pipeline investment, and domestic manufacturing expansion are critical levers. The company’s approach to pricing, tariffs, and business development may serve as a template for peers facing similar legacy product declines and regulatory uncertainty. Aesthetics category softness and competitive IBD dynamics highlight macro and category-specific risks for the broader sector. Investors should watch for further policy developments, pipeline readouts, and evidence of successful new product ramp as signals for both AbbVie and the wider industry.